The physical, emotional and interpersonal impact of HAART: Exploring the realities of HIV seropositive individuals on combination therapy

Journal of Health Psychology

Volumn 10, Issue 3, 2005, Pages 345-358

  Halkitis, Perry N ^a   Wilton, Leo ^b   Shrem, Michael T ^a   Zade, David D ^a  

^a NEW YORK UNIVERSITY   (United States)

^b BINGHAMTON UNIVERSITY   (United States)

Author keywords

HAART; Health care; HIV; Psychology; Psychosocial

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; EMOTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SOCIAL PSYCHOLOGY; SOCIAL WELFARE; STRESS; WELLBEING;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATTITUDE TO DEATH; FEMALE; FOCUS GROUPS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; INTERPERSONAL RELATIONS; MALE; SEXUAL BEHAVIOR;

EID: 19944418820     PISSN: 13591053     EISSN: None     Source Type: Journal    
DOI: 10.1177/1359105305051421     Document Type: Article

References (66)

1. Altice, F. L., Mostashari, F., & Friedland, G. H. (2001). Trust and acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 28, 47-58.
2. Blanch, J., Rousaud, A., Martinez, E., de Lazzari, E., Peri, J. M., Milinkovic, A., Perez-Cuevas, J. B., Blanco, J. L., & Gatell, J. M. (2002). Impact of lipodystrophy on the quality of life of HIV-1 infected patients. Journal of Acquired Immune Deficiency Syndromes, 31, 404-407.
3. Brechtl, J. R., Breitbart, W., Galietta, M., Krivo, S., & Rosenfeld, B. (2001). The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: Impact on medical, palliative care, and quality of life outcomes. Journal of Pain and Symptom Management, 21, 41-51.
4. Brenner, B. G., Turner, D., & Wainberg, M. A. (2002). HIV-1 drug resistance: Can we overcome? Expert Opinion on Biological Therapy, 2, 751-761.
5. Carrieri, P., Spire, B., Duran, S., Katlama, C., Peyramond, D., Francois, C., Chene, G., Lang, J. M., Moatti, J. P., Leport, C., & APROCO Study Group. (2003). Health-related quality of life after 1 year of highly active antitretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 32, 38-47.
6. Centers for Disease Control and Prevention (CDC). (1999). HIV/AIDS Surveillance Report, 10(2). Atlanta, GA: CDC.
7. Chan, K. S., Orlando, M., Joyce, G., Gifford, A. L., Burnam, M. A., Tucker, J. S., & Sherbourne, C. D. (2003). Combination antiretroviral therapy and improvements in mental health: Results from a nationally representative sample of persons undergoing care for HIV in the United States. Journal of Acquired Immune Deficiency Syndromes, 33, 104-111.
8. Cheever, L. W., & Wu, A. W. (1999). Medication adherence among HIV-infected patients: Understanding the complex behavior of patients taking this complex therapy. Current Infectious Disease Reports, 1, 401-407.
9. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., & Wu, A. W. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care, 12, 255-266.
10. Clotet, B., Ruiz, L., Martinez-Picado, J., Negredo, E., Hill, A., & Popescu, M. (2002). Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: A retrospective analysis of our clinical studies and two observational cohorts. HIV Clinical Trials, 3, 316-323.
11. Coates, T., Temoshok, L., & Mandel, J. (1984). Psychosocial research is essential to understanding and treating AIDS. American Psychologist, 39, 1309-1314.
12. Cohen, M. H., French, A. L., Benning, L., Kovacs, A., Anastos, K., Young, M., Minkoff, H., & Hessol, N. A. (2002). Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. American Journal of Medicine, 113, 91-98.
13. Cook, J. A., Cohen, M. H., Burke, J., Grey, D., Anastos, K., Kirstein, L., Palacio, H., Richardson, J., Wilton, T., & Young, M. (2002). Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. Journal of Acquired Immune Deficiency Syndromes, 30, 401-409.
14. Diaz, M. J., Cisek, T. J., Nionne, B., & Tottenham, N. (1999). Behavior practices regarding combination therapies for HIV/AIDS. Journal for Sex Education and Therapy, 24, 81-88.
15. Dionisio, D., Vivarelli, A., Zazzi, M., Esperti, F., Uberti, M., & Polidori, M. (2001). Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch. Clinical Infectious Diseases, 33, 706-709.
16. Durante, A. J., Bova, C. A., Fennie, K. P., Danvers, K. A., Holness, D. R. Burgess, J. D., & Williams, A. B. (2003). Home-based study of anti-HIV drug regimen adherence among HIV-infected women: Feasibility and preliminary results. AIDS Care, 15, 103-115.
17. Folch, E., Hernandez, I., Vetter, T., Browning, J., del Rio, C., & Lennox, J. (2002). AIDS-related mortality: Improved survival with HAART but causes of death unchanged. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February.
18. Fothergill-Bourbonnais F., Laschinger, S., Fillion, D., Denomme, N., Conway-Vendette, J., O'Reilly, L., Page, S., & Thibert, J. (2002). The experience of taking multiple drug therapies for persons with HIV infection: The Canadian perspective. Journal of the Association of Nurses in AIDS Care, 13, 32-42.
19. Gao, X., Nau, D. P., Rosenbluth, S. A., Scott, V., & Woodward, C. (2000). The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care, 12(4), 387-398.
20. Giordano, T. P., White, A. C., Jr, Sajja, P., Graviss, E. A., Arduino, R. C., Adu-Oppong, A., Lahart, C. J., & Visnegarwala, F. (2003). Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. Journal of Acquired Immune Deficiency Syndromes, 32, 399-405.
21. Grinberg, L. (1999). Honeymmon to HAARTache. POZ, 47, 80-85.
22. Halkitis, P., & Kirton, C. (1999). Self-strategies as means of enhancing adherence to HIV anitiretroviral therapies: A Rogerian approach. Journal of the New York State Nurse's Association, 30(2), 22-27.
23. Halkitis, P. N., Kutnick, A., Rosof, E., Slater, S., & Parsons, J. T. (2003). Adherence to HIV medications in a cohort of MSM: Impact of 9/11. Journal of Urban Health, 80, 161-166.
24. Halkitis, P. N., Parsons, J. T., Wolitski, R., & Remien, R. H. (2003). Adherence to HIV antiviral treatments in a community based sample of men who have sex with men. AIDS Care, 15, 89-102.
25. Halkitis, P. N., & Wilton, L. (1999). Beyond complacency: The effects of treatment advances on HIV transmission. Focus: A Guide to AIDS Research and Counseling, 14, 1-5.
26. Hays, R. D., Cunningham, W. E., Margot, K., & Beck, C. K. (1995). Health-related quality of life in HIV disease. Assessment, 2, 363-380.
27. Hays, R. D., & Morales, L. (2001). The RAND-36 measure of health-related quality of life. Annals of Medicine, 33, 350-357.
28. Holmes, W. C., & Pace, J. L. (2002). HIV-seropositive individuals' optimistic beliefs about prognosis and relation to medication and safe sex adherence. Journal of General Internal Medicine, 17, 677-683.
29. Human Resources and Services Administration. (1999). Hepatitis C. HRSA Care Action. Bethesda, MD: Human Resources and Services Administration.
30. Ickovics, J. R., & Meade, C. S. (2002). Adherence to HAART among patients with HIV: Breakthroughs and barriers. AIDS Care, 14, 309-318.
31. Ickovics, J. R., & Meisler, A. W. (1996). Adherence in AIDS clinical trials: A framework for clinical research and clinical care. American Journal of Medicine, 92(5), 492-502.
32. Kalichman, S. C., Nachmison, D., Cherry, C., & Williams, E. (1998). AIDS treatment advances and behavioral prevention setbacks: Preliminary assessment of reduced threat to HIV-AIDS. Health Psychology, 17, 546-550.
33. Kalichman, S. C., Ramachandran, B., & Ostrow, D. (1998). Protease inhibitors and the new AIDS combination therapies: Implications for psychological services. Professional Psychology: Research and Practice, 29, 349-356.
34. Karon, J., Fleming, P., Steketee, R., & de Cock, K. (2001). HIV in the United States at the turn of the new century: An epidemic in transition. American Journal of Public Health, 91, 1060-1068.
35. Lee, K., Solts, B., & Burns, J. (2002). Investigating the psychosocial impact of anti-HIV combination therapies. AIDS Care, 14, 851-857.
36. Melbourne, K. M. (1999). The impact of religion on adherence with antiretrovirals. Journal of the Association of Nurses in AIDS Care, 10(3), 99-100.
37. Miles, M. B., & Huberman, A. M. (1984). Qualitative data analysis. Newbury Park, CA: Sage Publications.
38. Miller, M., Meyer, L., Boufassa, F., Persoz, A., Sarr, A., Robain, M., Spira, A., & the SEROCO Study Group. (2000). Sexual behavior changes and protease inhibitor therapy. AIDS, 14, 33-39.
39. Miners, A. H., Sabin, C. A., Mocroft, A., Youle, M., Fisher, M., & Johnson, M. (2001). Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clinical Trials, 2, 484-492.
40. Newshan, G., Bennett, J., & Holman, S. (2002). Pain and other symptoms in ambulatory HIV patients in the age of highly active antiretroviral therapy. Journal of the Association of Nurses in AIDS Care, 13, 78-83.
41. Nicastri, E., Sarmati, L., d-Ettorre, G., Palmisano, L., Parisi, S. G., Uccella, I., Rianda, A., Concia, E., Vullo, V., Vella, S., & Andreoni, M. (2003). Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. Journal of Medical Virology, 69, 1-6.
42. Nieuwkerk, P. T., Gisolf, E. H., Reijfers, M. H., Lange, L. M., Danner, S. A., Sprangers, M. A., NATIVE Study Group, PROMETHEUS Study Group, & ADAM Study Group. (2001). Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS, 15, 1985-1991.
43. Oette, M., Juretzko, P., Kroidl, A., Sagir, A., Wettstein, M., Siegrist, J., & Haussinger, D. (2002). Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care and STDs, 16, 413-417.
44. Palella, F. J., Jr, Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A. et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338(13), 853-860.
45. Patton, M. Q. (2000). Qualitative evaluation and research, 3rd edn. Newbury Park, CA: Sage Publications.
46. Penedo, F. J., Gonzalez, J. S., Dahn, J. R., Antoni, M., Malow, R., Costa, P., & Schneiderman, N. (2003). Personality, quality of life, and HAART adherence among men and women living with HIV/AIDS. Journal of Psychosomatic Residence, 54, 271-278.
47. Powderly, W. G. (2002). Sorting through confusing messages: The art of HAART. Journal of Acquired Immune Deficiency Syndromes, 31, S3-S9.
48. Rabkin, J. G., & Ferrando, S. (1997). A 'second life' agenda: Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome. Archives of General Psychiatry, 54, 1049-1053.
49. Rabkin, J. G., Ferrando, S. J., Lin, S. H., Sewell, M., & McElhiney, M. (2000). Psychological effects of HAART: A 2-year study. Psychosomatic Medicine, 62, 413-422.
50. Remien, R. H., Hirky, A. E., Johnson, M. O., Weinhardt, L. S., Whittier, D., & Minh Le, G. (2003). Adherence to medication treatment: A qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four U.S. cities. AIDS and Behavior, 7, 61-71.
51. Riley, E. D., Bangsberg, D. R., Guzman, D., Perry, S., & Moss, A. (2003). Sustained use of antiretroviral therapy reduces mortality among HIV-infected homeless and marginally housed individuals living in San Francisco. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February.
52. Rodriguez-Rosado, R., Jimenez-Nacher, I., Soriano, V., Anton, P., & Gonzalez-Lahoz, J. (1998). Hepatoxicity after introduction of highly active antiretroviral therapy. AIDS, 12, 1256.
53. Roge, B. T., Katzenstein, T. L., Nielsen, H. L., & Gerstoft, J. (2003). Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART. HIV Medicine, 4, 38-47.
54. Saunders, D. S.. & Burgoyne, R. W. (2002). Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era. International Journal of STD and AIDS, 13(10), 683-690.
55. Schoennesson, L. N. (2002). Psychological and existential issues and quality of life in people living with HIV infection. AIDS Care, 14(3), 399-404.
56. Servais, J., Plesseria, J. M., Lambert, C., Fontaine, E., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., & Schmit, J. C. (2002). Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitor in patients developing HAART failure. Journal of Medical Virology, 67, 312-319.
57. Shor-Posner, G., Lecusay, R., Miguez, M.-J., Moreno-Black, G., Zhang, G., Rodriguez, N., Burbano, X., Baum, M., & Wilkie, F. (2003). Psychological burden in the era of HAART: Impact of selenium therapy. International Journal of Psychiatry in Medicine, 33(1), 55-69.
58. Tiamson, M. L. (2002). Challenges in the management of the HIV patient in the third decade of AIDS. Psychiatry Quarterly, 73, 51-58.
59. Valdez, H., Lederman, M. M., Woolley, I., Walker, C. J., Vernon, L. T., Hise, A., & Gripshover, B. M. (1999). Human immunodefieciency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome. Archives of Internal Medicine, 159, 1771-1776.
60. Valdiserri, R. O. (2003). Preventing new HIV infections in the U.S.: What can we hope to achieve? Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February.
61. Vanable, P. A., Ostrow, D. G., McKirnan, D. J., Taywaditep, K. J., & Hope, B. A. (2000). Impact of combination therapies on HIV risk perceptions and sexual risk taking among HIV-positive and HIV-negative gay and bisexual men. Health Psychology, 19, 34-145.
62. Van de Ven, P., Kippax, S., Knox, S., Prestage, G., & Crawford, J. (1999). HIV treatments optimism and sexual behaviour among gay men in Sydney and Melbourne. AIDS, 13, 2289-2294.
63. Van Vaerenbergh, K., de Geest, S., Derdelinckx, I., Bobbaers, H., Carbonez, A., Deschamps, A., de Graeve, V., de Saar, V., Ceunen, H., de Smet, K., Maes, B., Peetermans, W., Schrooten, Y., Desmyter, J., de Clercq, E., van Ranst, M., van Wijngaerden, E., & Vandamme, A. M. (2002). A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. Antiviral Chemistry and Chemotherapy, 13, 231-240.
64. Weidle, P. J., Ganea, C. E., Irwin, K. L., McGowan, J. P., Ernst, J. A., Olivo, N., & Holmberg, S. D. (1999). Adherence to antiretroviral medications in an inner-city population. Journal of Acquired Immune Deficiency Syndromes, 22, 498-502.
65. Wroe, A. L., & Thomas, M. G. (2003). Intentional and unintentional nonadherence in patients prescribed HAART treatment regimens. Psychology, Health and Medicine, 5(4), 453-463.
66. Yallop, S., Lowth, A., Fitzgerald, M. H., Reid, J., & Morelli, A. (2002). The changing world of HIV care: The impact on health professionals. Culture, Health and Sexuality, 4, 431-441.